结构导向设计和合成C22和C32修饰的FK520类似物,具有针对人类病原性真菌的增强活性
bioRxiv : the preprint server for biology
|October 10, 2024
概括
针对氨酸 (CaN) 的新抗真菌药物显示出治疗侵入性真菌感染的前景. 修改后的FK520衍生物具有强大的抗真菌活性,降低免疫抑制,改善治疗潜力.
科学领域:
- 菌类学和传染病的研究
- 结构生物学和药物设计
- 药理学 药理学是指药理学的学科.
背景情况:
- 侵入性真菌感染是全球主要的健康威胁,治疗选择有限.
- 现有的抗真菌药物面临挑战,包括毒性,有效性有限,以及新出现的耐药性.
- 氨酸 (CaN) 对于真菌病原发生是必不可少的,这使得它成为一个有吸引力的药物标.
研究的目的:
- 通过向真菌氨酸 (CaN) 来开发新的抗真菌剂.
- 设计具有强大的抗真菌活性和减少宿主免疫抑制的FK520衍生物.
- 改善氨酸抑制剂的治疗指数,用于治疗侵入性真菌感染.
主要方法:
- 利用致病性真菌CaN-FK506/FK520-FKBP12复合物的X射线晶体学.
- 采用基于结构的连接物设计和结构-活性关系 (SAR) 分析.
- 应用分子对接研究来开发和优化FK520衍生物 (例如C32修改).
主要成果:
- 开发了新的C22和C32修饰的FK520衍生物,具有强大的抗真菌活性.
- 鉴定了JH-FK-44 (一种C32修改的FK520衍生物),具有显著改善的治疗指数.
- NMR结合研究证实C32修饰破坏了人类的CaN结合,同时增强了真菌FKBP12相互作用.
结论:
- 氨酸抑制仍然是一个非常有前途的策略,用于开发新的抗真菌疗法.
- 修改后的FK520衍生物显示出更安全,更有效的抗真菌治疗的潜力.
- 基于结构的氨酸抑制剂的设计可以产生具有改善治疗特征的化合物.
相关概念视频
Structure-Activity Relationships and Drug Design
1.9K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.9K
Antifungal Agents
119
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to...
119
Anthelminthic Agents
103
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
103


